tenapanor Ibsrela
Selected indexed studies
- Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study. (Kidney360, 2024) [PMID:38323855]
- Tenapanor: First Approval. (Drugs, 2019) [PMID:31677150]
- Tenapanor. (, 2012) [PMID:37184198]
_Worker-drafted node — pending editorial review._
Connections
tenapanor Ibsrela is a side effect of
Sources
- Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. (2019) pubmed
- Tenapanor: First Approval. (2019) pubmed
- Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study. (2024) pubmed
- Tenapanor. (2012) pubmed
- Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM). (2021) pubmed
- A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY). (2021) pubmed
- Tenapanor (Ibsrela) for irritable bowel syndrome with constipation. (2022) pubmed
- Tenapanor. (2006) pubmed
- Tenapanor (Ibsrela) for the Treatment of Irritable Bowel Syndrome With Constipation. (2022) pubmed
- Efficacy of tenapanor in managing hyperphosphatemia and constipation in hemodialysis patients: A randomized controlled trial. (2025) pubmed